BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 36142405)

  • 1. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2.
    Timchenko L
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (CCUG)
    Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A
    Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of muscle atrophy in myotonic dystrophies.
    Timchenko L
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
    Meola G
    Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.
    Schneider-Gold C; Timchenko LT
    Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.
    Cerro-Herreros E; Chakraborty M; Pérez-Alonso M; Artero R; Llamusí B
    Sci Rep; 2017 Jun; 7(1):2843. PubMed ID: 28588248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
    Cho DH; Tapscott SJ
    Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myotonic dystrophies: clinical presentation, pathogenesis, diagnostics and therapy].
    Finsterer J; Rudnik-Schöneborn S
    Fortschr Neurol Psychiatr; 2015 Jan; 83(1):9-17. PubMed ID: 25602187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfunction of protein homeostasis in myotonic dystrophies.
    Meola G; Jones K; Wei C; Timchenko LT
    Histol Histopathol; 2013 Sep; 28(9):1089-98. PubMed ID: 23536431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism.
    Meola G; Cardani R
    J Neuromuscul Dis; 2015 Jul; 2(s2):S59-S71. PubMed ID: 27858759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.
    Meola G; Cardani R
    Biochim Biophys Acta; 2015 Apr; 1852(4):594-606. PubMed ID: 24882752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myotonic dystrophy: RNA pathogenesis comes into focus.
    Ranum LP; Day JW
    Am J Hum Genet; 2004 May; 74(5):793-804. PubMed ID: 15065017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2.
    Kamsteeg EJ; Kress W; Catalli C; Hertz JM; Witsch-Baumgartner M; Buckley MF; van Engelen BG; Schwartz M; Scheffer H
    Eur J Hum Genet; 2012 Dec; 20(12):1203-8. PubMed ID: 22643181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myotonic dystrophy types 1 and 2.
    Ashizawa T; Sarkar PS
    Handb Clin Neurol; 2011; 101():193-237. PubMed ID: 21496635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myotonic dystrophies.
    Huang CC; Kuo HC
    Chang Gung Med J; 2005 Aug; 28(8):517-26. PubMed ID: 16265841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2.
    Cardani R; Mancinelli E; Rotondo G; Sansone V; Meola G
    Eur J Histochem; 2006; 50(3):177-82. PubMed ID: 16920640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
    Mankodi A; Urbinati CR; Yuan QP; Moxley RT; Sansone V; Krym M; Henderson D; Schalling M; Swanson MS; Thornton CA
    Hum Mol Genet; 2001 Sep; 10(19):2165-70. PubMed ID: 11590133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?
    Fernandez-Gomez F; Tran H; Dhaenens CM; Caillet-Boudin ML; Schraen-Maschke S; Blum D; Sablonnière B; Buée-Scherrer V; Buee L; Sergeant N
    Adv Exp Med Biol; 2019; 1184():207-216. PubMed ID: 32096040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA pathogenesis of the myotonic dystrophies.
    Day JW; Ranum LP
    Neuromuscul Disord; 2005 Jan; 15(1):5-16. PubMed ID: 15639115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
    Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
    Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.